皇冠hg156体育下载地址carol gallagher joined nea in october, 2014. she is primarily focused on making biopharma investments. carol is a proven entrepreneur, operator and more recently investor with nearly 30 years of experience in commercial, drug development and business development roles. prior to joining nea she was a venture partner with frazier healthcare and she served as an independent director on multiple boards. from 2008-2011, carol was president and ceo of calistoga pharmaceuticals which developed the first-in-class therapeutic now marketed by gilead as zydelig.
皇冠hg156体育下载地址she currently serves as chairman of millendo and as a director at atarabio, annexon, chromacode, metacrine, pionyr immunotherapeutics, qpex biopharma, and turning point therapeutics.
- Carol Gallagher featured at The Atlantic's Innovation Pipeline Event
- Carol Gallagher featured at Salk Women & Science Event
- Carol Gallagher featured at BIO
- Carol Gallagher featured at AbbVie Collaboration Summit
- Carol Gallagher featured at Global Life Science Partnering Conference
- Carol Gallagher featured at San Diego Venture Group and Jansen Labs Life Science & Innovation Event